4 Stocks Whup The S&P 500 — And Yield More Than 30-Year Treasurys

“The thesis that these four stocks will beat the S&P and offer 5%+ yields is fragile unless rates retreat and the underlying cash flows prove durable; otherwise, risk of multiple compression and dividend cuts.”

The headline promises a dual win: stock gains plus 5%+ yields versus long Treasuries. But the takeaway misses why these four names have outperformed and what could snap that. MO and VZ offer high current yields, but they face regulatory, demand, and capex-cycle risks that can erode cash flow; PFE’s growth boosts rely on vaccines and new drugs that can disappoint; DOC Healthpeak is a REIT sensitive to rate moves and occupancy; and a sustained higher rate regime tends to compress REIT multiples and telecom valuations. If rates stay elevated or growth slows, the two way win looks more fragile than the article suggests.

“These stocks are not growth engines but rather value traps where dividend sustainability is increasingly threatened by stagnant top-line growth and high leverage.”

The premise of chasing yield-plus-growth in MO, PFE, DOC, and VZ ignores the 'yield trap' risk inherent in these specific names. While they currently outperform the S&P 500 YTD, this is largely a mean-reversion trade following years of significant underperformance. Pfizer is grappling with a post-pandemic revenue cliff, and Verizon’s massive debt load limits its ability to reinvest in infrastructure. Investors are essentially betting that these mature, slow-growth companies can maintain dividend payouts while interest rates remain elevated. This strategy conflates high current yield with total return potential, ignoring the fundamental headwinds that have suppressed these valuations for years.

“The article presents a 'have your cake and eat it too' narrative that ignores the risk these stocks are pricing in higher yields as a ceiling, not a floor, and outperformance may reverse if rates fall or earnings disappoint.”

The article conflates two separate return drivers—price appreciation and yield—without examining whether they're sustainable together. MO, PFE, DOC, and VZ are classic 'reach for yield' plays, typically owned by income investors. If their stock outperformance reflects multiple expansion (not earnings growth), that's mean-reversion risk, not a free lunch. The 5.2% Treasury yield is a real alternative cost: if rates stay elevated, dividend growth must accelerate to justify holding these over bonds. The article doesn't disclose whether YTD gains came from dividend reinvestment, multiple re-rating, or actual earnings beats—a critical omission.

“Elevated yields here signal compensation for fundamental risks, not a free lunch of market-beating returns plus income.”

The article spotlights MO, PFE, DOC and VZ for beating the S&P 500's 12.9% YTD return while yielding above the 5.2% on 30-year Treasurys. Yet this framing ignores that outsized yields usually price in sector-specific threats: MO's volume erosion and FDA risks, PFE's post-COVID revenue cliff, VZ's leverage and cord-cutting pressure, and DOC's sensitivity to higher rates that compress REIT valuations. Recent price gains may simply reflect mean-reversion from depressed levels rather than durable momentum, and payout ratios near or above 70% leave little margin if earnings disappoint.